AstraZeneca Pharma India has received approval from the CDSO for the import, sale, and distribution of Durvalumab.

Benchmark equity indices closed flat on Tuesday after hitting record highs. Nifty50 surpassed 26,000 and Sensex crossed ...

The Indian stock market witnessed a rollercoaster session on Tuesday as the benchmark indices, Sensex and Nifty 50, reached ...

Astrazeneca Pharma India has received CDSO's (Central Drugs Standard Control Organisation) nod for the import of Durvalumab ...

This surge came after the company announced approval to import and distribute Durvalumab (Imfinzi) infusion in two dosages.

The stock is trading above its 5-day, 10-day, 20-day, 30-day, 50-day, 100-day, 150-day, and 200-day simple moving averages ...

Bengaluru: AstraZeneca Pharma India Limited has received permission to import for sale and distribution of Durvalumab 120 ...

According to GLOBOCAN 2022 data, lung cancer remains the fourth most common cause of cancer-related mortality in India.

The stock jumped more than 12% to hit its lifetime high of Rs 7,598. The surge was as the company received Central Drugs ...

By Manvi Pant BENGALURU (Reuters) -Indian shares reached new record highs for the fourth consecutive session on Tuesday, ...

Metal stocks traded higher, with JSW Steel, Hindalco and Tata Steel climbing 2-3 percent on China stimulus hopes. Reliance Power jumped 5 percent after its board approved a prefer ...

Arcus Biosciences develops late-stage immunotherapies, with Domvanalimab and Casdatifan leading the way. See why I rate RCUS ...